

PEGLOTICASE (KRYSTEXXA®) PRESCRIBER ORDER FORM				
Patient Name:		Date of Birth:		Gender:
Address:				
Phone:	Height:	<input type="checkbox"/> inches <input type="checkbox"/> cm	Weight:	<input type="checkbox"/> lbs <input type="checkbox"/> kg
Clinical Information				
Primary Diagnosis Description: Gout (chronic)			ICD-10 Code:	
Date Methotrexate and Folic Acid Initiated:				
Pegloticase (Krystexxa®) Prescription				
Pegloticase (Krystexxa®) 8 mg/mL 2 mL SDV refill as directed x 1 year Infuse 8 mg IV over at least 2 hours every two weeks. Pharmacy to contact prescriber for serum uric acid levels greater than 6 mg/dL.				
Ancillary Orders				
Anaphylaxis Kit Dosage: <ul style="list-style-type: none"> ▪ SUBQ Doses: Epinephrine Auto-Injector 0.3 mg 2-Pack Kit – Inject 0.3 mg IM x 1 dose PRN anaphylactic reaction, repeat x 1 PRN. ▪ Diphenhydramine 25 mg (> 30 kg) or 1.25 mg/kg (≤ 30 kg) IV or IM; repeat x 1 in 15 min PRN no improvement. ▪ 0.9% Sodium Chloride 500 mL (> 30 kg) or 250 mL (≤ 30 kg) IV at KVO rate PRN anaphylaxis. 				
Medication Orders <input type="checkbox"/> Acetaminophen 1000 mg PO 30 min before infusion. <input type="checkbox"/> OTC PO antihistamine of choice and dose: _____ Take PO the night prior to infusion and take dose again 30 min prior to infusion. Patient may decline. Corticosteroid Pre-Medications: Select <i>ONE</i> of the following: <input type="checkbox"/> Solu-Cortef® 200 mg IV prior to infusion. <input type="checkbox"/> Methylprednisolone 80 mg IV prior to infusion. <input type="checkbox"/> Other: _____				
IV Flush Orders <input type="checkbox"/> <u>Peripheral:</u> 0.9% Sodium Chloride 2 to 3 mL pre-/post-use. <input type="checkbox"/> <u>Implanted Port:</u> 0.9% Sodium Chloride 5 to 10 mL pre-/post-use and 10 to 20 mL pre-/post-lab draw. Heparin (100 unit/mL) 3 to 5 mL post-use. For maintenance, heparin (100 unit/mL) 3 to 5 mL every 24 hr if accessed or weekly to monthly if not accessed.				
Lab Orders <input checked="" type="checkbox"/> Serum uric acid level drawn 1 to 2 days prior to each infusion following the initial infusion. Contact prescriber for serum uric acid levels greater than 6mg/dL. Recommend to dose Krystexxa as scheduled if first elevated level AND patient has not experienced any infusion reactions previously). If second consecutive elevated level greater than 6mg/dL, contact prescriber and discontinue Krystexxa. <input type="checkbox"/> Other: _____				
Skilled nurse to administer doses intravenously. Refill above ancillary orders as directed x 1 year. If patient is seen within a provider led infusion clinic, Option Care Health's infusion reaction management policy, skilled nursing plan of treatment, and IV flush administration will be followed per provider oversight. No individual anaphylaxis kit will be dispensed.				
<i>I certify that the use of the indicated treatment is medically necessary, and I will be supervising the patient's treatment.</i>				
Prescriber Signature: _____			Date: _____	
Prescriber Information				
Prescriber Name:		Phone:		Fax:
Address:		NPI:		
City, State:		Zip:	Office Contact:	
Fax completed form, insurance information, and clinical documentation to: 713-983-4647				
CONFIDENTIAL HEALTH INFORMATION: Healthcare information is personal information related to a person's healthcare. It is being faxed to you after appropriate authorization or under circumstances that don't require authorization. You are obligated to maintain it in a safe, secure, and confidential manner. Re-disclosure of this information is prohibited unless permitted by law or appropriate customer/patient authorization is obtained. Unauthorized re-disclosure or failure to maintain confidentiality could subject you to penalties described in federal and state laws. IMPORTANT WARNING: This message is intended for the use of the person or entity to whom it is addressed and may contain information that is privileged and confidential, the disclosure of which is governed by applicable law. If the reader of this message is not the intended recipient, or the employee or agent responsible for delivering it to the intended recipient, you are hereby notified that any dissemination, distribution or copying of this information is STRICTLY PROHIBITED. If you have received this message in error, please notify us immediately. Brand names are the property of their respective owners.				